Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Annals of Clinical Biochemistry|May 1, 1987
Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometriumO Sadan, B van Iddekinge, C J van Gelderen, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 19, 2018
Monitoring cognitive change in multiple sclerosis using a computerized cognitive batteryL De Meijer, D Merlo, O Skibina, et al.
AJNR. American Journal of Neuroradiology|February 5, 2022
Lesion Volume in Relapsing Multiple Sclerosis is Associated with Perivascular Space Enlargement at the Level of the Basal GangliaS C Kolbe, L M Garcia, N Yu, et al.
Neurology|September 30, 2009
Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophyA van der Walt, J Stankovich, M Bahlo, et al.
European Journal of Neurology|September 11, 2020
Speech metrics, general disability, brain imaging and quality of life in multiple sclerosisG Noffs, F M C Boonstra, T Perera, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 19, 2014
Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patientsM M Gresle, Y Liu, L F Dagley, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 15, 2024
Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programmeT A Hardy, P Aouad, M H Barnett, et al.
European Journal of Neurology|October 10, 2018
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort studyJ Lorscheider, J Kuhle, G Izquierdo, et al.
Journal of Medical Economics|December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United KingdomT Spelman, W L Herring, C Acosta, et al.
BMC Medical Research Methodology|May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosisM Lefort, S Sharmin, J B Andersen, et al.
Pageof 6